Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

195.00 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AbbVie

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
74 75 Next >
Healthcare Gems: 3 Essential Long-Term Stock Picks
Global healthcare spending reached a record $9 trillion in 2020. Catch the ongoing benefits with these three long-term healthcare stock picks. 
Via InvestorPlace
AbbVie's New $9B Neuroscience Space Deal Might Attract FTC Scrutiny, Analyst Signals
Wednesday, AbbVie Inc (NYSE: ABBV) agreed to acquire Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) for a total equity value of approximately $8.7 billion, or $45 per share in cash, with the... 
Via Benzinga
Why Methode Electronics Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Methode Electronics, Inc (NYSE: MEI) fell sharply during Thursday’s session following weak quarterly earnings. 
Via Benzinga
Is AbbVie Stock a Buy Now?
AbbVie's business could soon become more diversified. 
Via The Motley Fool
Decoding AbbVie's Options Activity: What's the Big Picture?
Via Benzinga
Analyst Ratings for AbbVie
Via Benzinga
Why Cerevel Therapeutics Stock Is Higher
Cerevel Therapeutics Holdings, Inc. 
Via Benzinga
Verint Reports Strong Earnings, Joins Semtech, Alphabet And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining more than 100 points on Thursday. 
Via Benzinga
Topics Stocks
Why Is Cerevel Therapeutics (CERE) Stock Up 12% Today?
Cerevel Therapeutics stock is climbing higher as CERE investors react to an $8.7 billion acquisition deal with AbbVie. 
Via InvestorPlace
Why Cerevel Therapeutics Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) jumped in pre-market trading after AbbVie Inc. (NYSE: ABBV) announced it will acquire the company for a total equity value of approximately... 
Via Benzinga
Health Care Company AbbVie Announces Acquisition of Immunogen
Via Benzinga
AbbVie Should Consider a Dividend Cut -- Here's Why
Dividend Kings with above-average yields have been badly underperforming the broader markets. 
Via The Motley Fool
Which Stock Is More Likely to Help You Retire as a Millionaire: AbbVie or Eli Lilly?
There's no guarantee that either of these big pharma stocks can help you retire as a millionaire. But one has a clear edge. 
Via The Motley Fool
Looking for Dividend Growth in the New Year? 3 Magnificent Stocks to Buy Now.
These particular players look cheap right now. 
Via The Motley Fool
Why Cerevel Therapeutics Holdings Is Moving After-Hours
Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) shares are trading higher in Wednesday's after-hours session after AbbVie Inc. (NYSE: ABBV) announced it will acquire the company for a total equity... 
Via Benzinga
7 High-Dividend Stocks to Buy for a Lifetime of Passive Income
These high-dividend stocks are among the biggest beneficiaries of current mega trends, and investors can leverage them for big gains. 
Via InvestorPlace
Small Cap, Big Potential: 3 Russell 2000 Stocks to Watch
The Russell 2000 index comprises small-cap companies, exposing investors to small organizations. Consider buying these Russell 2000 stocks. 
Via InvestorPlace
3 Stocks at the Forefront of Personalized Medicine Trend
Unveiling the impact of personalized medicine stocks, transforming patient care, and propelling market growth seamlessly 
Via InvestorPlace
ImmunoGen, AbbVie's $10B Deal Comes At 'Right Time' Analyst Says In Downgrade Note
AbbVie Inc (NYSE: ABBV) is acquiring ImmunoGen, Inc. (NASDAQ: IMGN) for around $ 
Via Benzinga
AbbVie's Big Buy Of ImmunoGen Opens Doors For Potential Investment Gains
AbbVie's $10.1 billion acquisition of ImmunoGen, with its promising ovarian cancer drug, Elahere, signals a strategic move in the competitive cancer drug market. Investors anticipate market reactions,... 
Via Talk Markets
2 Dividend Stocks to Buy and Hold Forever
These stocks offer much more than reliable dividends. 
Via The Motley Fool
5 S&P 500 Stocks That Pay a Generous Dividend
Investors are pocketing dividend yields between 4% and 9% with these stocks. 
Via The Motley Fool
Topics Stocks
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
Software earnings were strong, while the Fed is shifting toward rate cuts. 
Via Investor's Business Daily
Topics Economy Stocks
ImmunoGen Stock Nearly Doubled On Thursday: What Happened?
Shares of ImmunoGen Inc. close to doubled this morning after AbbVie Inc. said it will buy the cancer therapies company for $10.1 billion. 
Via Talk Markets
Why Abbvie Stock Popped Today
The company announces a major deal worth over $10 billion. 
Via The Motley Fool
ImmunoGen's Flagship Cancer Therapy Draws AbbVie's Attention With $10.1B Deal
AbbVie Inc (NYSE: ABBV) has agreed to acquire ImmunoGen Inc (NASDAQ: IMGN) and its flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC)... 
Via Benzinga
Why Is ImmunoGen (IMGN) Stock Up 81% Today?
ImmunoGen stock is taking off on news that AbbVie is acquiring all outstanding shares of IMGN in a $10.1 billion acquisition deal. 
Via InvestorPlace
AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal
IMGN stock soared after AbbVie agreed to buy ImmunoGen for $10.1 billion, offering a rich premium for the maker of cancer drug Elahere. 
Via Investor's Business Daily
Mastering Market Trends: The 7 Best Blue-Chip Stocks for Today’s Economy
These are the best blue-chip stocks for investors to consider among a group of already strong equities available in the market. 
Via InvestorPlace
AbbVie's Lung Cancer Study Shows Encouraging Clinical Benefits In Subtype Of Patients
AbbVie Inc (NYSE: ABBV) announced topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal... 
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.